Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone vs. Insulin Glargine in T2D Secondary Drug Failure
NCT00609856Phase 4Completed
- Sponsor
- Skåne University Hospital
- Start
- Apr 2004
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pioglitazone in type 2 diabetes mellitus (T2DM), sponsored by Skåne University Hospital. Primary endpoints: Beta-cell function at 26 weeks and Insulin sensitivity at 26 weeks. Started Apr 2004; status: completed.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00609856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00609856.